ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,496.77
      0.99%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Inventiva (IVA)

      7. Inventiva (IVA) News

      IVA

      Inventiva (IVA)

      Inventiva
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:IVA
      DateTimeSourceHeadlineSymbolCompany
      01/31/20224:00PMGlobeNewswire Inc.Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiationEU:IVAInventiva
      01/20/20224:00PMGlobeNewswire Inc.Inventiva annonce sa participation à plusieurs conférences investisseurs en janvier et février 2022EU:IVAInventiva
      01/20/20224:00PMGlobeNewswire Inc.Inventiva announces participation at several conferences in January and February 2022EU:IVAInventiva
      01/20/20224:00PMGlobeNewswire Inc.Inventiva announces participation at several conferences in January and February 2022EU:IVAInventiva
      01/14/20222:00AMGlobeNewswire Inc.Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler CheuvreuxEU:IVAInventiva
      01/14/20222:00AMGlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
      12/16/20214:00PMGlobeNewswire Inc.Inventiva to present at the 40th Annual J.P. Morgan Healthcare ConferenceEU:IVAInventiva
      12/16/20214:00PMGlobeNewswire Inc.Inventiva to present at the 40th Annual J.P. Morgan Healthcare ConferenceEU:IVAInventiva
      12/16/20214:00PMGlobeNewswire Inc.Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »EU:IVAInventiva
      12/06/20214:00PMGlobeNewswire Inc.Inventiva announces positive results of clinical thorough QT study conducted with lanifibranorEU:IVAInventiva
      12/06/20214:00PMGlobeNewswire Inc.Inventiva announces positive results of clinical thorough QT study conducted with lanifibranorEU:IVAInventiva
      12/06/20214:00PMGlobeNewswire Inc.Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranorEU:IVAInventiva
      11/10/20214:00PMGlobeNewswire Inc.Inventiva reports 2021 Third Quarter Financial InformationEU:IVAInventiva
      11/10/20214:00PMGlobeNewswire Inc.Inventiva publie ses informations financières du 3ème trimestre 2021EU:IVAInventiva
      11/10/20214:00PMGlobeNewswire Inc.Inventiva reports 2021 Third Quarter Financial InformationEU:IVAInventiva
      11/03/20214:00PMGlobeNewswire Inc.Inventiva organise un webcast avec des leaders d’opinion à l’occasion du congrès The Liver Meeting™ 2021 de l’AASLDEU:IVAInventiva
      11/03/20214:00PMGlobeNewswire Inc.Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  EU:IVAInventiva
      11/03/20214:00PMGlobeNewswire Inc.Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  EU:IVAInventiva
      10/29/20219:29AMGlobeNewswire Inc.Inventiva announces participation at several conferences in November 2021EU:IVAInventiva
      10/29/20219:29AMGlobeNewswire Inc.Inventiva announces participation at several conferences in November 2021EU:IVAInventiva
      10/29/20219:29AMGlobeNewswire Inc.Inventiva annonce sa participation à plusieurs conférences investisseurs en novembre 2021EU:IVAInventiva
      10/27/20214:00PMGlobeNewswire Inc.Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetesEU:IVAInventiva
      10/27/20214:00PMGlobeNewswire Inc.Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2EU:IVAInventiva
      10/27/20214:00PMGlobeNewswire Inc.Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetesEU:IVAInventiva
      10/20/20215:07PMGlobeNewswire Inc.« The New England Journal of Medicine » publie les résultats de l’étude clinique de Phase IIb NATIVE d’Inventiva avec lanifibranor dans la NASHEU:IVAInventiva
      10/20/20215:07PMGlobeNewswire Inc.The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASHEU:IVAInventiva
      10/20/20215:07PMGlobeNewswire Inc.The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASHEU:IVAInventiva
      10/18/20214:00PMGlobeNewswire Inc.Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLDEU:IVAInventiva
      10/18/20214:00PMGlobeNewswire Inc.Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021EU:IVAInventiva
      10/18/20214:00PMGlobeNewswire Inc.Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021EU:IVAInventiva
       Showing the most relevant articles for your search:EU:IVA

      Your Recent History

      BIT
      SAF
      Safran
      Delayed Upgrade Clock